Audit: QRS - Inositol for Health & Longevity of the ER frontmatter

Audit conducted on 25/08/2026 11:08 using AI4L / Grok 4

Iterations

Summary

Items	Count
Total	93
Passed	84
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Protocol doses, gates, benefit/risk headings, markers, cadence, and at-a-glance claims match ER Protocol, Key Interactions & Contraindications, Expected Benefits, Potential Risks, Monitoring, and Conclusion.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“theoretical blunting of lithium’s central effect”, “Valproate (caution, limited data)”, “independent confirmation is limited”, and “Cycle regularity is contested” track the ER.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Decision-gate thresholds (12–18 g/day, recurrent hypoglycemia, specialist follow-up) are kept; “Modest” on BMI is stripped only under the benefits no-qualifier rule.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Stop items match Populations who should avoid; caution items match Key Interactions; benefits/risks match those ER sections.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs, expert names, or brand names appear in the QRS body.
1.6	The QRS does not introduce new attributions.	🟢	No new attributions added.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Same contested-evidence, metabolic-tool framing as the ER Conclusion.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Presents a usable 4 g/day metabolic protocol while stating limits and non-indications.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Doses and gates are presented as ER facts; footer is educational distillation.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No “should”, “recommend”, or “advise” in variable content.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Protocol and gates report ER content rather than instructing the reader.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person address in variable content.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	At-a-glance uses plain terms; remaining clinical labels (HOMA-IR, SGLT2, PCOS) are ER labels required elsewhere.
2.8	Information is presented in a concise and very compact manner	🟢	Tier lines, gate bullets, and protocol cells are one-line condensations.
2.9	It DOES NOT address the reader directly	🟢	No direct address in variable content.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Frames a 4 g metabolic tool with HOMA-IR targets and contested fertility use.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Split 2 g dosing, 8–12 week labs, and home glucose if on insulin/sulfonylureas.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Functional marker targets and split-dose saturation detail are not general-population framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Positions inositol as a metabolic tool in insulin-resistant adults, not a general aging supplement.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	Uses “longevity” / “aging supplement”; no “anti-aging”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Uses myo-inositol, sulfonylureas, HOMA-IR, triglycerides; at-a-glance “plaque-linked cholesterol” is the 7.4 plain-language rendering of LDL.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All listed headings, gate titles, tier labels, and column headers match the required strings.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	page_title, header, at_a_glance, action_1–3, time_1–3, benefits/risks tiers, stop/caution, marker_1–8, monitoring_cadence, and qualitative_item_1–6 are present.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	website=”evidence_review”, website=”audit”, and website=”full_review” template spans are unmodified.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No QRS-mapped ER section is empty. Medium-tier risks have no items and are handled by 13.5 (display:none), not empty-state phrasing.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels “Metabolic / PCOS default”, “Time of day”, and “40:1 combination” match the ER bold labels.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Protocol, gate, benefit, risk, and marker labels match ER headings or bold labels.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji in the QRS; ER ⚠️ Conflicted markers are not carried over.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Benefits, risks, gates, and cadence are condensed to single lines; monitoring keeps the ER’s eight markers as required by 14.2.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	First element after doctype is the metadata comment.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening and closing — present; preamble “QRS — Metadata…” is before the opening —.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment only.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Values are trimmed; duration “00:07” is quoted because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: inositol_2026-0825-0451_Grok_ER.md
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02 matches QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0825-1006
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Grok
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word: Grok
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Grok 4
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	Grok 4 = nickname + version, no extra qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: inositol_2026-0825-0451_Grok_QRS.html
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Same as 5.4; values are trimmed.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Inositol for Health & Longevity - Quick Reference Sheet”
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“Inositol for Health & Longevity”
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0825-1006 → 08/25/2026
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Grok 4
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header is title plus the standard Created-on / AI4L subline only.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	4 g/day metabolic tool in insulin-resistant adults, trial outcomes, contested cycles, not fertility/aging, nausea and additive glucose lowering.
7.2	[at_a_glance] is no longer than 60 words	🟢	60 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Dose, population, lipid/insulin outcomes, contested cycles, fertility/aging non-claims, and GI/glucose limits are in the Conclusion.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“polycystic ovary syndrome” not PCOS; “plaque-linked cholesterol” not LDL; no HOMA-IR or NCT IDs.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, n, or p-values.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No effect sizes or risk ratios.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Five stop items match the ER “Populations who should avoid Inositol” list.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Recurrent hypoglycemia, high-dose DCI fertility, 12–18 g plus lithium, bipolar at 12–18 g without specialist follow-up, IP6 if mineral-deficiency risk.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Five <li> elements inside [stop_items].
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Trailing ER clauses (“given conflicting oocyte-quality data”, “until a larger safety study exists”, “given case reports of manic switch”) are stripped; no dash-trailers.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	12–18 g/day, “when glucose cannot be monitored”, “without specialist follow-up”, and iron/zinc-deficiency risk are kept.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER contraindication bullets do not use ranking notation.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	ER names five avoid populations; the section is not empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Caution list is taken from that ER section’s interaction bullets.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Ten real interactions are listed; “none identified” OTC analgesics and folate/α-lactalbumin are omitted. Insulin/sulfonylureas, lithium, and IP6 remain as distinct interaction gates (general caution / high-dose / mislabel), not copies of the narrower stop populations.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Ten <li> elements inside [caution_items].
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Each item is the ER bold label only; trailing mechanistic sentences are stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drugs and rank tags (caution / monitor / limited data / mislabeled) are kept.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER interaction bullets do not use ranking notation of that kind.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	ER names multiple interactions; the section is not empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Content is from Therapeutic Protocol (default dose, time of day, 40:1 combination, absorption split).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Metabolic/PCOS 2 g twice daily, breakfast/dinner split, and 40:1 combination — the primary dose, timing/split, and main alternative.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER Protocol lists more than three actionable aspects.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine action fields are filled from the ER Protocol bullets.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Insulin/HOMA-IR (8 weeks), sperm (3 months), and sleep (same night to a few days / 10-week pregnancy trial) are the distinct TTE facts with the strongest related benefits.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Insulin resistance, sperm, and sleep are Medium-tier benefits with explicit timings; High-tier lipid/BP share the same 8-week metabolic window the ER attributes to insulin/HOMA-IR; Low-tier cycle and panic timings are omitted.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER provides more than three TTE aspects (insulin, cycles, panic, sleep, sperm).
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine time fields are filled from Practical Considerations, Protocol, and Benefits.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	ER Practical Considerations includes a Time to effect bullet.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All High, Medium, Low, and Speculative headings from Expected Benefits appear.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans are present and populated.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Headings only; “Modest” stripped from BMI; no magnitudes or citations.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content in the benefit lines.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers have items.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	High, Low, and Speculative headings match that ER section; Medium has no items there.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans are present.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	ER risk headings only; “theoretical” kept as ER cautious phrasing on the lithium item.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content in the risk lines.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	[risks_medium] has style=”display:none”; not filled with empty-state phrasing.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Derived from Monitoring Protocol & Defining Success.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eight table biomarkers (fasting insulin through TSH) are listed with matching targets and why text.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Baseline insulin/glucose/lipids (androgens and cycle log in PCOS); repeat at 8–12 weeks then every 6–12 months; home glucose 2–4 weeks if on insulin or sulfonylureas.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Taken from the Qualitative markers list in Monitoring Protocol & Defining Success.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers are listed verbatim.

Issues 25/08/2026 11:08

Pass rate 100.00%. No issues found.

Issues 25/08/2026 10:50

1. 1.3 — Panic qualifier dropped: Qualitative Assessment item 4 is “Panic frequency”, dropping the ER Monitoring limiter “(only if a high-dose protocol is in use)” and shortening “Panic-attack frequency”, which broadens the item from high-dose psychiatric use to all users.

Fixes 25/08/2026 10:50

1. 1.3 — Panic qualifier dropped: Restored qualitative item 4 from “Panic frequency” to the ER wording “Panic-attack frequency (only if a high-dose protocol is in use)”.

Issues 25/08/2026 10:43

1. 1.3 — Claim strengthened or softened: At-a-glance says “Cycle and fertility effects are contested” (ER Conclusion: cycle regularity is contested; fertility is “not a settled fertility drug”). Stop item 1 broadens “who cannot monitor glucose after adding a sensitizer” to “without glucose monitoring”. Qualitative item 4 adds “only if a high-dose protocol is in use”, which the Monitoring section does not restrict.

2. 8.5 — Sensitizer time-window dropped: First stop item omits the time-window qualifier “after adding a sensitizer” from ER “People with recurrent hypoglycemia on insulin or sulfonylureas who cannot monitor glucose after adding a sensitizer.”

3. 12.3 — Modest magnitude qualifier: Medium benefits keep the effect-size qualifier “modest” in “modest reduction in body mass index” rather than the key fact alone.

Fixes 25/08/2026 10:47

1. 1.3 — Claim strengthened or softened: At-a-glance now uses ER Conclusion phrasing: “Cycle regularity is contested. It is not a settled fertility drug or a general aging supplement.” Qualitative item 4 is “Panic frequency”, without the added high-dose restriction.

2. 8.5 — Sensitizer time-window dropped: Stop item 1 is now “Recurrent hypoglycemia on insulin or sulfonylureas when glucose cannot be monitored after adding a sensitizer.”

3. 12.3 — Modest magnitude qualifier: Medium benefits now read “reduction in body mass index” instead of “modest reduction in body mass index”.

Issues 25/08/2026 10:29

1. 4.3 — Invented time-to-effect label: time_1_label is “Insulin and lipids”; the ER Practical Considerations time-to-effect bullet describes insulin and HOMA-IR shifts at 8 weeks, not a combined “insulin and lipids” label.

2. 4.3 / 9.5 — Interaction labels abbreviated: Key Interaction items drop or rewrite ER bold-label parentheticals. Severity classes (caution)/(monitor) are omitted, “Lithium (caution at high dose)” is rewritten as “Lithium (4 g/day)”, “Valproate (caution, limited data)” is shortened to “Valproate”, and “Selenium (additive in thyroid protocols)” / “IP6 / phytate products (caution if mislabeled as inositol)” lose part of the parenthetical.

Fixes 25/08/2026 10:29

1. 4.3 — Invented time-to-effect label: Changed time_1_label from “Insulin and lipids” to “Insulin and HOMA-IR”, matching the ER Practical Considerations time-to-effect wording.

2. 4.3 / 9.5 — Interaction labels abbreviated: Restored ER bold-label parentheticals on Key Interaction items, including (caution)/(monitor) severity classes, “Lithium (caution at high dose)”, “Valproate (caution, limited data)”, “Selenium (additive in thyroid protocols)”, and “IP6 / phytate products (caution if mislabeled as inositol)”.

Issues 25/08/2026 10:13

1. 12.3 — Speculative benefit qualifiers: benefits_speculative appends “not shown” to both ER speculative headings (“Healthspan gain in insulin-sensitive adults not shown; protection against Alzheimer disease not shown”). Item 12.3 requires the key fact only, with no qualifiers; the ER headings do not include “not shown”.

Fixes 25/08/2026 10:13

1. 12.3 — Speculative benefit qualifiers: Removed the added “not shown” qualifier from both speculative benefit items so they match the ER headings: “Healthspan gain in insulin-sensitive adults; protection against Alzheimer disease”.